OTC Medicine Topical (cream / gel / ointment) • Dicarboxylic acid; anti-acne & depigmenting agent
✓ Medically Reviewed Monograph

Azelaic Acid

Also known as / Synonyms: Azelaic Acid, Dicarboxylic Acid, Anti-Melasma Gel

Gentle dermatological cream that treats acne, calms rosacea redness, and fades dark skin spots without bleaching fabrics.

Medically reviewed by Dr. Lisa Matthews, PharmD BCPS · Clinical Pharmacist
Written by 4mg Clinical Pharmacology Team Last reviewed ✓ Clinically Verified
📋

Clinical Snapshot & Specifications

Generic Name: Azelaic Acid
Active Ingredient: Azelaic Acid
Dosage Form: Topical (cream / gel / ointment)
Available Strengths: 10%, 15%, 20% w/w topical cream and gel
Prescription Status: Both Rx and OTC strengths exist (verified)
Approved Routes:
Topical
Popular Verified Brands:
Aziderm Picspot Finacea Skinoren (India)
Regulatory Standards: Approved by CDSCO; Schedule H prescription drug in India. US FDA approved for acne vulgaris and inflammatory papulopustular rosacea.
🎯

Approved Indications & Medical Uses

  • Topical treatment of mild-to-moderate inflammatory acne vulgaris (papules and pustules).
  • Topical treatment of inflammatory papules and pustules of mild-to-moderate rosacea.
  • Management of epidermal melasma and post-inflammatory hyperpigmentation (PIH).
  • Safe and effective alternative to retinoids and hydroquinone during pregnancy and in patients with sensitive skin.
🚫

Contraindications (Do Not Use If…)

Known hypersensitivity to azelaic acid, propylene glycol, or formulation excipients.

🛡️

Important Clinical Precautions & Warnings

  • Initial transient tingling and burning: mild stinging, burning, or itching occurs in up to 30% of patients during the first 1 to 2 weeks; usually subsides with continued use; apply a moisturizer first if stinging is prominent.
  • Does not bleach normal skin or fabrics: unlike hydroquinone, azelaic acid selectively inhibits abnormal, hyperactive melanocytes; unlike benzoyl peroxide, it does not bleach colored fabrics or hair.
  • Wash hands after application: apply a thin film twice daily (morning and evening) to clean, dry skin; avoid contact with eyes, nose, and mouth.
  • Hypopigmentation monitoring: patients with dark complexions should be monitored for localized loss of normal skin pigmentation (hypopigmentation).
  • Sun protection: use broad-spectrum sunscreen daily, especially when treating melasma or hyperpigmentation.

Special Populations (Paediatric & Geriatric Care)

Pediatric: Approved for acne vulgaris in pediatric patients aged 12 years and older. Geriatric: Safe and effective for rosacea and facial hyperpigmentation in older adults.

⚡

Side Effects & Adverse Reactions

ℹ️ Common Side Effects (Usually Mild)

Transient burning, stinging, tingling, pruritus, skin dryness, mild erythema, and localized peeling.

🚨 Serious Side Effects — Seek Urgent Medical Care

Severe allergic contact dermatitis, facial angioedema, localized hypopigmentation (loss of skin color), and worsening of asthma (rare).

Action: Discontinue medication and seek immediate medical attention or call emergency services if any serious symptom occurs.

🔄

Drug, Food & Substance Interactions

  • No known systemic drug interactions with topical administration.
  • Can be combined safely with topical clindamycin, erythromycin, or oral antibiotics for severe inflammatory acne.
🤰

Pregnancy & Lactation Clinical Safety

Pregnancy Safety:

Azelaic acid is an endogenous saturated dicarboxylic acid (FDA Category B). Systemic absorption is minimal (~4%), and extensive animal and clinical data show no teratogenicity. It is the first-line treatment of choice for acne, rosacea, and melasma during pregnancy.

Lactation & Breastfeeding:

Only negligible amounts enter systemic circulation. Less than 4% is absorbed, which is unlikely to alter natural breast milk composition. It is safe for nursing mothers.

📦

Storage, Administration & Overdose Protocol

🌡️ Recommended Storage:

Store below 25°C (77°F). Protect from freezing. Keep tube tightly closed.

⏱️ Missed Dose Protocol:

Apply at the next scheduled time. Do not apply extra gel or cream to compensate.

📚

Clinical Sources & Regulatory References

Statutory drug monograph citations and regulatory databases consulted for clinical synthesis.

Every clinical monograph on 4mg.in is continuously cross-referenced against official pharmacopoeias, national formulary compendia, and statutory regulatory filings to guarantee therapeutic precision:

🏛️ CDSCO (Govt. of India)

Central Drugs Standard Control Organisation, Ministry of Health and Family Welfare. Evaluated for approved indications, Schedule H/H1 status, and National List of Essential Medicines (NLEM).

CDSCO Official Portal →
🇺🇸 U.S. FDA / DailyMed

U.S. Food and Drug Administration Approved Prescribing Information, Package Inserts, and Pharmacovigilance Black Box Warnings repository via NLM DailyMed.

Search FDA Labels on DailyMed →
🌐 World Health Organization

WHO Model List of Essential Medicines (23rd List) and WHO Collaborating Centre for Drug Statistics Methodology (Anatomical Therapeutic Chemical - ATC / DDD Index).

WHO Essential Medicines Registry →
🔬 PubMed / NLM

National Center for Biotechnology Information (NCBI). Peer-reviewed clinical trials, bioavailability investigations, and Cochrane systematic reviews.

Query PubMed Studies for Azelaic Acid →
Suggested Monograph Citation:

4mg Clinical Pharmacology Team. Azelaic Acid Monograph: Uses, Dosage, Contraindications & Interactions. Medically reviewed by licensed clinical editors. 4mg.in, 2026. Available at: https://4mg.in/medicines/azelaic-acid/

🛡️
Clinical & Legal Disclaimer: The clinical monographs and drug information published on 4mg.in are strictly intended for educational, clinical reference, and informational utility. They do not constitute personalized medical advice, diagnosis, or treatment regimens. Always seek the advice of a registered physician or licensed pharmacist regarding specific clinical conditions, prescription dosages, and potential contraindications. Review our comprehensive Editorial & Clinical Fact-Checking Policy.